PDCD1 and neoplasm: Subsequently, antibodies targeting programmed cell death-1 (PD-1; nivolumab, pembrolizumab, and cemiplimab) (4–6) or its ligand, programmed cell death ligand-1 (PD-L1; atezolizumab, avelumab, and durvalumab) (7–9) have also gained approvals and become integrated into the standard-of-care in many tumor types.